Archive for the ‘Gene Therapy Research’ Category

Dublin, June 15, 2020 (GLOBE NEWSWIRE) -- The "Global Gene Therapy Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2014 including financial terms where available including over 340 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2014.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking2.1. Introduction2.2. Gene therapy partnering over the years2.3. Most active Gene therapy dealmakers2.4. Gene therapy partnering by deal type2.5. Gene therapy partnering by therapy area2.6. Deal terms for Gene therapy partnering

Chapter 3 - Leading Gene therapy deals3.1. Introduction3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers4.1. Introduction4.2. Most active Gene therapy dealmakers4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

A selection of the companies mentioned include:

For more information about this report visit https://www.researchandmarkets.com/r/6xcnxy

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Link:
Gene Therapy Global Partnering Terms and Agreements Directory of Deals by the World's Leading Healthcare Companies from 2014-2020 - Yahoo Finance UK

The global Gene Therapy for Rare Disease Market research report thoroughly explains each and every aspect related to the Gene Therapy for Rare Disease Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of a thorough examination offers in-depth information regarding the global Gene Therapy for Rare Disease Market. A pathway of development is offered by the market to the several connected networks of businesses under it, which include different firms, industries, organizations, vendors, distributors, and local manufacturers too. All the key Gene Therapy for Rare Disease Market players compete with each other by offering better products and services at a reasonable price in order to grab significant share at the regional and global level market.

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2321

This report sample includesBrief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Top Manufacturers in GlobalGene Therapy for Rare DiseaseMarket Includes:Kite Pharma, Inc. (Gilead Sciences, Inc.), Novartis International AG, Juno Therapeutics Inc. (Celgene Corporation), Bluebird Bio, Inc., Spark Therapeutics, Inc., uniQure N.V, Orchard Therapeutics Plc., PTC Therapeutics, Inc., and BioMarin Pharmaceutical Inc.

Regions & Countries Mentioned In The Gene Therapy for Rare Disease Market Report:

Key Highlights of the Table of Contents:

Gene Therapy for Rare Disease Market Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global market, years considered, and study objectives. Furthermore, it tuches the segmentation study provided in the report on the basis of the type of product and applications.

Gene Therapy for Rare Disease Market Executive Summary: This section emphasizes on the key studies, market growth rate,Competitive landscape, market drivers, trends, and issues.

Gene Therapy for Rare Disease Market Production by Region: The report provides information related to import and export, production, revenue, and key players of all regional markets studied are covered in this section.

Gene Therapy for Rare Disease Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2321

Table of Contents

Report Overview:It includes the Gene Therapy for Rare Disease market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Gene Therapy for Rare Disease market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Gene Therapy for Rare Disease market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Gene Therapy for Rare Disease market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Get Download PDF Brochure https://www.coherentmarketinsights.com/insight/request-pdf/2321

Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

About CMI:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154, U.SPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Visit link:
Gene Therapy for Rare Disease Market: Top Global Players Competition with Production, Consumption, Revenue and Gross Margin by 2026 - Medic Insider

BDRP Virtual Annual Meeting

RESTON, Va. (PRWEB) June 16, 2020

Some of the worlds leading scientists will be recognized for their research on birth defects, including alcohol and cannabinoid exposure on brain development, caffeine exposure during pregnancy, and gene-environmental interactions in autism. The special lectures and awards will be presented at the Society for Birth Defects Research and Preventions (BDRP) first-ever Virtual Annual Meeting June 25, 29 and 30, as well as July 1 and 2, 2020.

At a fraction of the cost of its traditional in-person Annual Meeting, the BDRP virtual presentations will also cover other hot topics such as the latest birth defects research surrounding opioids, gene therapy, and obesity in pregnancy. For the full Virtual Annual Meeting schedule, including opportunities for Continuing Medical Education credits, please visit https://birthdefectsresearch.org/meetings/2020/.

The Society for Birth Defects Research and Prevention is an international and multidisciplinary group of scientists including researchers, clinicians, epidemiologists, and public health professionals from academia, government, and industry who study birth defects, reproduction, and disorders of developmental origin. Through its 2020 awards, the unique diversity of the birth defects research field is underscored. Our foundation as a multi-disciplinary society led the way for innovative research that continues to move us toward a healthier future, said Chris Curran, PhD, BDRP President. As scientists, we have always recognized the transformative power of diversity in the many disciplines represented in the Society and we hope to inspire more scientists of all backgrounds to get involved in this rewarding research.

The 2020 Society for Birth Defects Research and Prevention award recipients and special lecturers include:

Keynote LectureDiana W. Bianchi, MD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Scheduled Presentation: Prenatal Genomic Medicine: Transforming Obstetric Practice and Delivering New Biological Insights

Josef Warkany Lecture Linda S. Birnbaum, PhD, DABT, ATS, Scientist Emeritus and Former Director, National Institute of Environmental Health Sciences and National Toxicology ProgramScheduled Presentation: POPs: A Plethora of Developmental Effects

Robert L. Brent Lecture: Teratogen UpdateKaren W. Gripp, MD, FAAP, FACMG, A.I. duPont Hospital for Children/NemoursScheduled Presentation: From Dysmorphology to Next-Generation Phenotyping

F. Clarke Fraser New Investigator Award Joshua F. Robinson, PhD, University of California, San FranciscoScheduled Presentation: Establishing a Research Program in Developmental Toxicology Utilizing In Vitro Models and Big Data Approaches

Agnish Fellowship Elaine M. Faustman, PhD, University of WashingtonScheduled Presentation: Educating Future Birth Defects Researchers: Opportunities in the Era of Personalized Medicine, Systems Biology, and CRISPR Technologies

James G. Wilson Publication Award for the best paper published in the journal Birth Defects ResearchKristen R. Breit, PhD, San Diego State University The effects of alcohol and cannabinoid exposure during the brain growth spurt on behavioral development in rats; Birth Defects Research 111.12: 760-774 (2019)

Society for Birth Defects Research and Prevention Innovator Award Finalists

Title: ReproTracker: A Human Stem Cell-Based Biomarker Assay for In Vitro Assessment of Developmental Toxicity.

Title: Studying Gene-Environmental Interactions in Autism with iPSC-derived BrainSpheres: microRNA and Metabolic Biomarkers of the Synergy.

Edward W. Carney Distinguished Service Award Alan M. Hoberman, PhD, DABT, ATS, Charles River

Marie W. Taubeneck AwardBevin Blake, PhD, NTPL/NIEHS

Edward W. Carney Trainee Awards

FASEB Howard Garrison Public Affairs FellowshipMona Dai, PhD Student, Harvard University

Birth Defects Research Distinguished Scholar Awards

For a full list of Society for Birth Defects Research and Prevention awards and recipients, please visit: https://www.birthdefectsresearch.org/meetings/2020/am-awards.asp

About the Society for Birth Defects Research and PreventionThe Society for Birth Defects Research and Prevention (BDRP) is made up of nearly 700 members worldwide specializing in a variety of disciplines, including developmental biology and toxicology, reproduction and endocrinology, epidemiology, cell and molecular biology, nutritional biochemistry, and genetics as well as the clinical disciplines of prenatal medicine, pediatrics, obstetrics, neonatology, medical genetics, and teratogen risk counseling. Scientists interested in BDRP membership are encouraged to visit http://www.BirthDefectsResearch.org.

Media Contact: Nicole Chavez, 619-368-3259, nchavez@birthdefectsresearch.org

Continue reading here:
Diverse Birth Defects Research and the Science of Tomorrow to Be Recognized by the Society for Birth Defects Research and Prevention - PR Web

New Jersey, United States,- A detailed research study on Hemophilia Gene Therapy Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Hemophilia Gene Therapy, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=274190&utm_source=COD&utm_medium=888

Leading Hemophilia Gene Therapy manufacturers/companies operating at both regional and global levels:

Hemophilia Gene Therapy Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Hemophilia Gene Therapy market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Hemophilia Gene Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Hemophilia Gene Therapy Market, By Product

Hemophilia Gene Therapy Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=274190&utm_source=COD&utm_medium=888

Hemophilia Gene Therapy Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Hemophilia Gene Therapy market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Hemophilia Gene Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Hemophilia Gene Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Hemophilia Gene Therapy Market, By Deployment Model

5.1 Overview

6 Hemophilia Gene Therapy Market, By Solution

6.1 Overview

7 Hemophilia Gene Therapy Market, By Vertical

7.1 Overview

8 Hemophilia Gene Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Hemophilia Gene Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=274190&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Acoustic Emission Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Construction Robot Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Electric Commercial Vehicle Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

The rest is here:
Hemophilia Gene Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

With the coronavirus pandemic forcing scientific research labs to close around the globe, it seems almost inevitable that the ongoing crisis will accelerate the growing demand for remote drug development. A number of European companies see this as an opportunity to introduce computer-aided biology and robot-driven labs.

In recent years, the pharmaceutical industry has been increasingly struggling with the rising costs of developing new drugs due to factors ranging from the complexity of diseases like cancer to stringent regulatory hurdles. Now, in a bid to boost the productivity of R&D pipelines and reduce costs, new technologies are promising to automate traditionally laborious and time-consuming tasks in the drug development process.

In the same way that Amazon Web Services changed the software industry by allowing businesses to outsource their entire IT infrastructure, several European biotechs are developing technology that allows labs to automatically conduct and analyze biological experiments in remote robotic labs.

A survey conducted in April suggested that 48% of scientific research labs across the globe had been forced to close temporarily due to the ongoing coronavirus pandemic. Hence, the crisis could accelerate the uptake of automation technology in research labs.

There has already been a shift towards computer-aided biology for the last 18 months, explained Peter Crane, corporate strategy manager at Synthace, one of the biotechs developing such technology.

Covid-19 has acted as an accelerant. Synthace has seen an increasing interest in our approach, and we expect this will continue to grow more rapidly post Covid-19. There has been a huge amount of disruption caused by Covid-19, and we believe that once this has eased, people will seriously begin to re-evaluate how they are conducting their science, and there will be a market bump regarding the adoption of new technologies within pharma and academia.

Over the past two decades, industries such as the semiconductor and automotive sectors have increasingly embraced next-generation automation technologies as a means of reducing costs while simultaneously increasing product complexity.

Crane pointed out that in this regard, the biotechnology industry as a whole currently lags behind. While automation is used to a certain extent, it is mainly at the two extreme ends of the drug development process, both in repeatedly screening thousands of compounds against a drug target and in manufacturing the finished product.

[There] is this huge middle bit where experiments are still done at the bench, he said. But were seeing interest from people looking at how they can use technology to get more done with fewer people in the lab.

This is mainly because designing and carrying out such experiments is a highly dynamic process, one which has previously been beyond the realm of machines. However, recent advances in machine learning and robotic systems offer new possibilities.

Synthaces cloud software platform which is already being used by companies in Europe and the US, including Merck and Microsoft enables scientists to design experimental protocols from their laptops via a graphical user interface. These are then converted into instructions that a robot can understand, and transmitted to a remote lab.

While a technician is still required to set up the robot with the reagents and labware specified in the experimental design, the vast majority of the process is done virtually. Once the experiment is completed, the data is automatically collated, structured, and returned to the user.

Likewise, UK-based biotech Arctoris has also designed a platform that enables scientists to simulate and then run a range of experiments in a remote robotic lab. In the eyes of Arctoris co-founder and CEO, Martin-Immanuel Bittner, the flexibility offered by this kind of technology will make it far easier for budding entrepreneurs to bring new concepts to the market.

It enables any researcher worldwide to start a biotech company with a laptop and a credit card, said Bittner. You dont need a lab anymore, you dont have to worry about equipment purchases and maintenance. So instead of restricting drug discovery research to a few centers that can afford all the specialist equipment, we enable the brightest minds to contribute to the enormous challenges that we are facing in chronic illnesses such as cancer, heart disease, and neurodegeneration.

As well as saving time and cost, the other main advantage of automating experiments comes from reducing human error, and so consistently generating reliable data. With regulatory and due diligence standards in drug development becoming ever more stringent, generating high quality and fully auditable data has never been more important.

Bittner said that there is already evidence to suggest that automating experiments and data collation processes can make it easier for companies to attract early-stage venture capital funding.

Several of our clients have told us that the VCs they spoke with for their next funding round put a lot of emphasis on whether the data they showed to back up their hypotheses was trustworthy or not, he explained. In this context, automated data collection allows a full audit of every step taken.

In a regulated environment such as biopharma, it is absolutely critical to be able to demonstrate to regulators what happened when. We enable that down to the minute an experiment was conducted.

Eliminating human error could help tackle one of the root causes of the declining productivity in drug discovery in recent decades, which is a lack of reproducibility. Only 10 to 20% of all published laboratory findings can be reproduced by independent third parties, wasting billions in R&D funding, said Bittner. This has a devastating effect. Automation could get around this issue by ensuring that experiments are conducted in exactly the same way no matter how long apart.

Two sectors where automation could have the biggest impact in the decade to come are the growing cell and gene therapy industries. While both have been heralded as a means to cure many of the worlds rare diseases, the sheer cost of such therapies has so far been prohibitive. To give just one example, a gene therapy for spinal muscular atrophy developed by Novartis is currently sold at $2.1 million in the US.

Automating the mechanics of treatments based on genetic engineering techniques such as CRISPR gene editing could make it possible for companies to scale up the production of such therapies on demand, which could dramatically reduce the cost.

Synthego, a company working on automating genome engineering, has declared its intention to ultimately make cell and gene therapies as accessible as vaccines.

Our primary goal with Synthego is to break through the barriers to entry for world-class quality life science research, said Paul Dabrowski, CEO of Synthego. Our platform minimizes the variables and risks in biological research by automating workflows, controlling quality, scaling for massive experiments, and reducing cost structures.

Synthego has built a suite of genome editing products that allow any scientist to outsource their CRISPR needs and use these molecular tools without needing to be an expert in the area themselves, thus opening up the field to a much broader range of researchers. For example, one of their packages enables researchers to get a gene knockout in one of several hundred cell lines.

In the coming years, the company intends to offer more complex modifications, enabling both academia and industry to access CRISPR gene editing while continuing to focus on their specific area of expertise.

Its empowering cell biologists with the tools of molecular biology without having to learn all those details, said Dabrowski. This is following the model of cloud technology, where companies rent out remote server farms to handle their computing needs instead of relying on their own hardware. Well be able to do their full research workflow.

All in all, there seems to be no doubt that the Covid-19 pandemic will change the face of drug discovery and development. As researchers around the globe are faced with remote work, automation technology for biology laboratories seem to have reached their time to shine and change the way drug development is done.

Cover illustration by Anastasiia Slynko, images via Shutterstock and Synthego

Read more:
Drug Development in Covid-19 Times: Is Going Remote the... - Labiotech.eu

With a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global Gene Therapy market as well as the factors responsible for such a growth. Our highly dedicated professionals have inputted critical and accurate insights associated with every industry, and region by doing thorough primary and secondary research. The global Gene Therapy market is poised to expand at a CAGR of over xx% during the forecast period (2020-2026).

The recent report on the global Gene Therapy market published by the Fact.MR includes the impact of COVID-19 on the Gene Therapy market. Severe economic crisis are being faced by each and every country of the world. This has affected each and every market in the world and it will take a good amount of time to recover. The Gene Therapy market study includes the current market scenario on the global platform and also forecasts the market development during the forecast period. We leverage space-age industrial and digitalization tools to provide avant-garde actionable insights to our clients regarding the Gene Therapy market. For enhancing readers experience, the report starts with a basic overview about the Gene Therapy and its classification.

Request for Sample Report @ https://www.factmr.com/report/4648/gene-therapy-market

The Gene Therapy market report includes global as well as emerging players:

The insights for each vendor consists of:

Regional Analysis

Important regions covered in the Gene Therapy market report include:

The Gene Therapy market report also provides data regarding the key countries in the defined regions.

Segmentation Analysis

By Product:

By end use:

Send an Enquiry @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4648

What insights does the Gene Therapy market report provide to the readers?

Questionnaire answered in the Gene Therapy market report include:

And many more

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Continue reading here:
Impact of COVID-19 Crisis on Gobal Gene Therapy Market Demand and Consumption Growth, Predicts Fact.MR - The Cloud Tribune

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced today that it has expanded its program for the manufacture of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for its lead drug candidate, Oncoprex immunogene therapy, by entering into a new agreement with manufacturing partner Aldevron, LLC, (Aldevron). The new agreement provides for production of TUSC2 plasmid DNA, the active agent in Oncoprex, at full commercial scale. The Companys manufacturing at this scale should also result in significantly lower costs per unit of product manufactured due to economies of scale.

Genprexs upcoming clinical trials include a Phase I/II trial of Oncoprex combined with osimertinib (marketed by AstraZeneca as Tagrisso) for non-small cell lung cancer (NSCLC), which received Fast Track Designation in January 2020 and is expected to be initiated in early 2021. A clinical trial of Oncoprex in combination with pembrolizumab (marketed by Merck as Keytruda) in NSCLC is also planned.

We are pleased with continued progress in the scale-up of our manufacturing processes. This new agreement with Aldevron increases our manufacturing capabilities in support of our clinical trials utilizing Oncoprex immunogene therapy in combination with targeted therapies and immunotherapies against lung cancer, said Rodney Varner, Chairman and Chief Executive Officer of Genprex.

Our team is excited about the expansion of our manufacturing agreement and elevation of our long-standing relationship with Genprex, said Michelle Berg, President of GMP Nucleic Acids at Aldevron. Aldevrons GMP facility and campus buildout ensures we can meet the future manufacturing demands of companies experiencing significant growth such as Genprex; thereby enabling our ultimate goal of impacting the lives of patients.

Oncoprex consists of TUSC2 plasmid DNA encapsulated in a lipid nanoparticle. The TUSC2 gene is the active agent in Oncoprex. Data indicate that the resultant product when transfected into cancer cells both induces cell signaling that triggers programmed cell death and modulates the immune system so that the cancer cells are more susceptible to treatment.

About Aldevron

Aldevron serves the biotechnology industry offering in-stock products and custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-Source quality system. It is currently constructing a second manufacturing site on its headquarter campus in Fargo, North Dakota, more than doubling its production capacity. It has additional facilities in Madison, Wisconsin, and Freiburg, Germany. To learn more, visit http://www.aldevron.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, Oncoprex, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of Oncoprex, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our products; the timing and success of obtaining FDA approval of Oncoprex and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Read the original post:
Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex Clinical Development - Business Wire

Researchers at the University of Florida announced Wednesday plans to develop a potential COVID-19 vaccine using a gene therapy approach that has been used to treat rare neuromuscular diseases.

The therapy technique would use a harmless virus, used to package and deliver a gene from SARS-CoV-2 (the virus that causes COVID-19 disease), to help combat a harmful virus. While the gene therapy vaccine is unable to replicate on its own, it is strong enough to trigger virus-neutralizing antibodies against the live virus, according to a UF press release.

Dr. Barry Byrne, a rare-disease researcher and pediatrics professor at UF, has begun testing two vaccine candidates in animal models. Virology experts at UFs Emerging Pathogens Institute anticipate having initial results this month that will determine if the vaccines can induce an effective antivirus response.

The gene therapy technique, which uses a harmless adeno-associated virus (AAV) has been used to develop treatments for other diseases, and researchers are now trying to use AAV to block SARS-CoV-2 virus from entering cells.

Using AAV has some potential advantages over traditional vaccine development, said Dr. Byrne, director of the UF Powell Gene Therapy Center, such as the fact that the therapy has been widely studied so researchers likely wont have to spend as much time testing its safety. It also may take effect rapidly and prove more durable than other types of vaccines.

The research team has tested two closely related vaccine candidates in rodents. By August, Dr. Byrne hopes to start a yearlong trial phase to evaluate the safety and effectiveness of the vaccines in 100 adult volunteers.

Dr. Byrne and his team are striving to develop a universal vaccine to take into account future SARS-CoV-2 genetic drifts and to address the issue of viral mutations that have already been documented. Developing a universal vaccine could take 18 months, according to the universitys press release.

This is a virus that can change very rapidly. That is concerning because it means any vaccine made today may be ineffective tomorrow, Dr. Byrne said.

There are no licensed vaccines that use AAV, but 25 viral vector vaccines are under development. Globally, there are more than 130 vaccine candidates in various stages of development. Both Moderna and Johnson & Johnson have announced that human trials of their vaccine candidates will start in July.

See the original post here:
University of Florida researchers trying to develop universal coronavirus vaccine using gene therapy - Washington Times

Biological Safety Testing Market Scenarios and Brief Analysis with size, status and forecast 2020-2026

The global research report titled Biological Safety Testing Market has recently published by The Research Insights which helps to provide guidelines for the businesses. It has been aggregated on the basis of different key pillars of businesses such as drivers, restraints and global opportunities. This research report has been compiled by using primary and secondary research techniques. While curating this research report several dynamic aspects of businesses such as definition, classification, application, and industrial chain structure have been studied in detail. It sheds light on dynamic aspects of the businesses such as the clients needs and feedback of the various customers. Finally, researchers direct its focus on some significant points to give a gist about investment, profit margin, and revenue.

Get Free Sample Copy of This Report: https://www.theresearchinsights.com/request_sample.php?id=87190

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Biological Safety Testing Market: Lonza Group, SGS SA, WuXiPharmaTech, BSL Bioservice, Merck KGaA, Cytovance Biologics, Toxikon Corporation, Charles River Laboratories International, Sigma-Aldrich Corporation, Avance Biosciences

Global Biological Safety Testing Market Split by Product Type and Applications:

This report segments the global Biological Safety Testing Market on the basis of Types are:

Adventitious Agents Detection Test

Cell Line Authentication and Characterization tests

Bioburden Testing

Endotoxin Tests

Sterility Testing

Residual Host Contaminant Detection Tests

Others

On the basis of Application, the Global Biological Safety Testing Market is segmented into:

Blood Products

Stem Cell Products

Cellular and Gene Therapy Products

Tissue Products

Others

Browse the report description and TOC:

https://www.theresearchinsights.com/life-science/Biological-Safety-Testing-Market-Research-Global-StatusForecast-by-Geography-TypeApplication-2016-2026-87190

Regional analysis of Global Biological Safety Testing Market:

Geographically, the global Biological Safety Testing market has been fragmented into several regions such as North America, Latin America, Asia-Pacific, Africa, and Europe on the basis of productivity of several companies. Each and every segment along with its sub-segments are analyzed in the research report. The competitive landscape of the market has been elaborated by studying numerous factors such as top manufacturers, prices and revenue.

The information on the global Biological Safety Testing market is accessible to readers in logical chapter wise format. Driving and restraining factors have been listed in this research report which helps to provide the understanding of positive as well as negative aspects in front of the businesses.

Key questions answered in this report:

-What are the top key players of the global Biological Safety Testing market?

-What are the strengths of the global Biological Safety Testing market?

-What are the trends, challenges, threats, and opportunities in front of the businesses?

-What are the effective sales methodologies?

-what are the different marketing and distribution channels?

Buy Exclusive Report :

https://www.theresearchinsights.com/checkout?id=87190

Some major points from Table of Content:

Global Biological Safety Testing Market Research Report 2020-2026

Chapter 1: Industry Overview

Chapter 2: Biological Safety Testing Market International and China Market Analysis

Chapter 3: Analysis of Revenue by Classifications

Chapter 4: Analysis of Revenue by Regions and Applications

Chapter 5: Analysis of Biological Safety Testing Industry Key Manufacturers

Chapter 6: Sales Price and Gross Margin Analysis

Chapter 7: Development Trend of Market 2020-2026.

Continued ..

About us:

The Research Insights A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us :

Robin

Sales manager

Contact number: +91-996-067-0000

[emailprotected]

https://www.theresearchinsights.com

Read more:
Biological Safety Testing Market Research, Developments and Precise Outlook 2020 to 2026 - 3rd Watch News

Data Bridge Market Researchhas added an exhaustive research study of theGlobal Choroideremia Treatment Marketdetailing every single market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The research report presents a complete assessment of the market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

Global Choroideremia Treatment Marketis expected to grow at a steady CAGR in the forecast period of 2019-2026.Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Global Choroideremia Treatment Market By Treatment Type (Gene Therapy, Surgery), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Forecast to 2026

Download exclusive PDF sample report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-choroideremia-treatment-market

Some of the major competitors currently working in the global choroideremia treatment market areBiogen, 4D Molecular Therapeutics, Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant AG, F. Hoffmann-La Roche Ltd and others.

Market Definition:

Choroideremia is also known as choroidal sclerosis is a rare, degenerative, X-linked inherited retinal disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina due to Mutations in the CHM gene. This CHM gene required to produce Rab escort protein-1 (REP-1). The condition gets its name from the distinctive sweet odor of affected infants urine and is also c, a protein that takes part in targeting vesicles (small sacs of substances) into, out of, and within cells.

According to the statistics published by U.S. Department of Health & Human Services, an estimated population of choroideremia is about 1 in 50,000-100,000 people. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Segmentation:Global Choroideremia Treatment Market

By Treatment

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Download Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-choroideremia-treatment-market

Key Developments in the Market:

Competitive Analysis:

Global choroideremia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global choroideremia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Order a Copy of Global Choroideremia Treatment Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-choroideremia-treatment-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read the original:
Choroideremia Treatment Market 2020 Industry Analysis, Share, Size, Demand, Forecast to grow at a steady CAGR | Copernicus Therapeutics, Inc, Wize...

SAN DIEGO & OSAKA, Japan Neurocrine Biosciences, Inc. (Nasdaq:NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced a strategic collaboration to develop and commercialize compounds in Takedas early-to-mid-stage psychiatry pipeline. Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.

We are excited to collaborate with Takeda to bring life-changing therapies to people living with serious, challenging and under-addressed psychiatric disorders who are in need of better treatment options, said Kevin Gorman, Ph.D., Chief Executive Officer at Neurocrine Biosciences. With our deep understanding in the fields of psychiatry and neurology, we look forward to developing new treatments for schizophrenia, treatment-resistant depression and anhedonia as part of our diverse clinical development pipeline. This strategic partnership enhances our growing pipeline and strengthens our position as a leading neuroscience-focused biopharmaceutical company.

With longstanding experience developing and commercializing therapies for serious neurological and psychiatric disorders, Neurocrine Biosciences is the ideal partner to continue to develop our early-to-mid-stage psychiatry portfolio and bring these potential new therapies to patients, said Sarah Sheikh, M.D., M.Sc., MRCP, Head, Neuroscience Therapeutic Area Unit at Takeda. Takeda is deeply committed to Neuroscience as one of our core therapeutic areas. The strategic partnership with Neurocrine Biosciences allows us to continue to build on our leadership in psychiatry and deliver future medicines for these patients while advancing our clinical assets for rare neurological diseases, such as narcolepsy, developmental and epileptic encephalopathies and neurodegenerative conditions.

Collaboration Details

Under the terms of the agreement, Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration. Takeda will receive a total of $120 million USD in upfront cash. Additionally, Takeda will be entitled to development milestones of up to $495 million USD, commercial milestones of up to $1.4 billion USD and up to double-digit royalties on net sales. At certain development events, Takeda may elect to opt in or out of a 50:50 profit share on all clinical programs on an asset-by-asset basis. For any asset in which Takeda is participating in a 50:50 profit share arrangement, Takeda will not be eligible to receive development or commercial milestones.

Conference Call Information

Today, Neurocrine Biosciences will host a conference call and webcast at 8:00 a.m. ET to provide commentary on the collaboration. The live call may be accessed by dialing (866) 831-8711 (U.S.) or (203) 518-9883 (International) using the conference ID: 5022. A live audio webcast of the conference call will be available online on the Neurocrine Bioscience website under Investors at http://www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Programs in the Collaboration Agreement

TAK-831

TAK-831 is a potential first-in-class D-Amino Acid Oxidase (DAAO) inhibitor that has completed multiple Phase I studies and is currently in on-going Phase II studies, including the Phase II INTERACT proof-of-concept study in negative symptoms of schizophrenia.

TAK-653

TAK-653 is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) potentiator. TAK-653 has completed Phase I studies and is a Phase II study-ready compound with the potential to be developed for treatment-resistant depression.

TAK-041

TAK-041 is a potential first-in-class G Protein-Coupled Receptor 139 (GPR139) agonist. TAK-041 has completed multiple Phase I studies and is a Phase II study-ready compound with the potential to be developed for the treatment of anhedonia in depression. Anhedonia is a psychological condition characterized by the inability to experience pleasure.

Preclinical Programs

The collaboration includes the rights to four preclinical programs.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The companys diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinsons disease endometriosis* and uterine fibroids* and clinical development programs in multiple therapeutic areas including a gene therapy for Parkinsons disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

Takedas Commitment to Neuroscience

Takedas Neuroscience therapeutic area is driven by the immense unmet need of patients suffering from neurological diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these patients. Our commitment to patients extends beyond our research and development efforts by supporting several neuroscience patient and provider organizations to raise awareness, educate and broaden access to therapies.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in peoples lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Neurocrine Biosciences Forward-Looking Statements

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the benefits to be derived from transactions with Takeda Pharmaceutical Company Limited; our potential milestone and royalty payments to Takeda; the development of our product candidates and the timing of completion of our clinical, regulatory, and other development activities. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions; risks and uncertainties related to any COVID-19 quarantines, shelter-in-place and similar government orders that are currently in place or that may be put in place in the future, including the impact of such orders on our business operations and the business operations of the third parties on which we rely; our future financial and operating performance; risks or uncertainties related to the development of the our product candidates; risks that the FDA or other regulatory authorities may make adverse decisions regarding our product candidates; risks that clinical development activities may not be completed on time or at all; risks that clinical development activities may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for a product candidate; risks that the benefits of the agreements with Takeda may never be realized; risks that our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Companys periodic reports filed with the Securities and Exchange Commission, including without limitation the Companys quarterly report on Form 10-Q for the quarter ended March 31, 2020. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.

Takeda Pharmaceutical Company Limited Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could anticipates, estimates, projects or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s); and other factors identified in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: https://www.takeda.com/investors/reports/sec-filings/ or at http://www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takedas future results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005101/en/

Contacts

Neurocrine Biosciences, Inc.

Media Navjot Rai +1-858-617-7623 media@neurocrine.com

Investors Todd Tushla +1-858-617-7143 ir@neurocrine.com

Takeda Pharmaceuticals

Media in Japan Kazumi Kobayashi +81 (0) 3-3278-2095 kazumi.kobayashi@takeda.com

Media Outside Japan Monique Kelley +1-857-600-3488 monique.kelley@takeda.com

#distro

Follow this link:
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders - Financial Post

The Cell and Tissue Culture Supplies Market research provides a brief analysis comprising both primary and secondary research. The report provides the perception of all the key factors somehow affecting Cell and Tissue Culture Supplies Market. It also includes the degree of competition, product development and opportunities in the global Cell and Tissue Culture Supplies market which makes it more suitable for market analysis. Moreover, the report covers the latest trends, product dynamics, geographical segmentation and regulatory framework regarding Cell and Tissue Culture Supplies market.

Request a Sample Copy of the Report https://www.regalintelligence.com/request-sample/141804

Cell and Tissue Culture Supplies Market prominent players:Stemcell Technologies, Wheaton Industries, GE Healthcare, Thermo Fisher Scientific, VWR International, Merck KGaA, Lonza Group, Corning, Promocell GmbH, Eppendorf AG

Global Cell and Tissue Culture Supplies market report covers all the key players, driving and restraining factors and opportunities in upcoming years. The report provides the historical revenue of the market, latest trends, market size and utilization for the reference regarding the political and technical environment of Cell and Tissue Culture Supplies market share.

Enquire or share your queries if any before purchasing the report-

Market segmentation

Market segmentation by type: Consumable Products, Instruments

Market segmentation by application: Vaccine Production, Biopharmaceutical Production, Toxicity Testing, Gene Therapy, Drug Screening & Development, Cancer Research, Other

Get Detailed Table of [emailprotected] https://www.regalintelligence.com/request-toc/141804

Cell and Tissue Culture Supplies market segmentation by region:

The report provides a brief analysis considering both quality and quantity data predicted to provide opportunities evolving the market growth in the forecasting period. Majorly focusing on factors that might affect the market growth makes it more informative.

Key points covered in Report: The information covered in this report are Introduction, Key findings, Market overview, PEST/SWOT Analysis. Factors affecting the growth, Market Size and Trends, Market Segmentation with regional analysis is also included. Assessment with industry overview, company profile and conclusion is also mentioned respectively.

Important Points from Table of Contents:

Global Cell and Tissue Culture Supplies Market Professional Survey Report 20191 Report Overview1.1 Definition and Specification1.2 Manufacturers and Region Overview1.2.1 Manufacturers Overview1.2.2 Regions Overview1.3 Type Overview1.3.1 Consumable Products1.3.2 Instruments1.4 Application Overview1.4.1 Vaccine Production1.4.2 Biopharmaceutical Production1.4.3 Toxicity Testing1.4.4 Gene Therapy1.4.5 Drug Screening & Development1.4.6 Cancer Research1.4.7 Other1.5 Industrial Chain1.5.1 Cell and Tissue Culture Supplies Industrial Chain1.5.2 Upstream1.5.3 Downstream2.1 The Overall Market Performance(Volume)2.1.1 Consumable Products2.1.2 Instruments2.2 The Overall Market Performance(Value)2.2.1 Consumable Products2.2.2 Instruments3 Global Cell and Tissue Culture Supplies Market Assessment by Application3.1 Overall Market Performance (Volume)3.2 Vaccine Production3.3 Biopharmaceutical Production3.4 Toxicity Testing3.5 Gene Therapy3.6 Drug Screening & Development3.7 Cancer Research3.8 Other4 Competitive Analysis4.1 Stemcell Technologies4.1.1 Stemcell Technologies Profiles4.1.2 Stemcell Technologies Product Information4.1.3 Stemcell Technologies Cell and Tissue Culture Supplies Business Performance4.1.4 SWOT Analysis4.2 Wheaton Industries4.2.1 Wheaton Industries Profiles4.2.2 Wheaton Industries Product Information4.2.3 Wheaton Industries Cell and Tissue Culture Supplies Business Performance4.2.4 SWOT Analysis4.3 GE Healthcare4.3.1 GE Healthcare Profiles4.3.2 GE Healthcare Product Information4.3.3 GE Healthcare Cell and Tissue Culture Supplies Business Performance4.3.4 SWOT Analysis4.4 Thermo Fisher Scientific4.4.1 Thermo Fisher Scientific Profiles4.4.2 Thermo Fisher Scientific Product Information4.4.3 Thermo Fisher Scientific Cell and Tissue Culture Supplies Business Performance4.4.4 SWOT Analysis4.5 VWR International4.5.1 VWR International Profiles4.5.2 VWR International Product Information4.5.3 VWR International Cell and Tissue Culture Supplies Business Performance4.5.4 SWOT Analysis4.6 Merck KGaA4.6.1 Merck KGaA Profiles4.6.2 Merck KGaA Product Information4.6.3 Merck KGaA Cell and Tissue Culture Supplies Business Performance4.6.4 SWOT Analysis4.7 Lonza Group4.7.1 Lonza Group Profiles4.7.2 Lonza Group Product Information4.7.3 Lonza Group Cell and Tissue Culture Supplies Business Performance4.7.4 SWOT Analysis4.8 Corning4.8.1 Corning Profiles4.8.2 Corning Product Information4.8.3 Corning Cell and Tissue Culture Supplies Business Performance4.8.4 SWOT Analysis4.9 Promocell GmbH4.9.1 Promocell GmbH Profiles4.9.2 Promocell GmbH Product Information4.9.3 Promocell GmbH Cell and Tissue Culture Supplies Business Performance4.9.4 SWOT Analysis4.10 Eppendorf AG4.10.1 Eppendorf AG Profiles4.10.2 Eppendorf AG Product Information4.10.3 Eppendorf AG Cell and Tissue Culture Supplies Business Performance4.10.4 SWOT Analysis5 Competitive Lanscape5.1 Global Cell and Tissue Culture Supplies Capacity (K Units) and Market Share of Manufacturers (2014-2020)5.2 Global Cell and Tissue Culture Supplies Sales (K Units) and Market Share of Manufacturers (2014-2020)5.3 Global Cell and Tissue Culture Supplies Revenue (M USD) and Market Share of Manufacturers (2014-2020)5.4 Global Cell and Tissue Culture Supplies Price (USD/Unit) of Manufacturers (2014-2020)5.5 Global Cell and Tissue Culture Supplies Gross Margin of Manufacturers (2014-2020)5.6 Market Concentration

Purchase this Report https://www.regalintelligence.com/buyNow/141804

Thank You.

See the original post here:
Cell and Tissue Culture Supplies Market to Witness Widespread Expansion During 2020 to 2026 - Cole of Duty

Prophecy Market Insights Viral Vector and Plasmid DNA Manufacturing market research report focuses on the market structure and various factors affecting the growth of the market. The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Viral Vector and Plasmid DNA Manufacturing market over the forecast period (2019-2029).

The data and information required in the market report are taken from various sources such as websites, annual reports of the companies, journals, and others and were validated by the industry experts. The facts and data are represented in the Viral Vector and Plasmid DNA Manufacturing report using diagrams, graphs, pie charts, and other clear representations to enhance the visual representation and easy understanding the facts mentioned in the report.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3817

The Viral Vector and Plasmid DNA Manufacturing research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The predictions mentioned in the market report have been derived using proven research techniques, assumptions and methodologies. This Viral Vector and Plasmid DNA Manufacturing market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

All the key players mentioned in the Viral Vector and Plasmid DNA Manufacturing market report are elaborated thoroughly based on R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. Also, the report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Viral Vector and Plasmid DNA ManufacturingMarket Key Companies:

Segmentation Overview:

Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

Global Viral Vector and Plasmid DNA Manufacturing Market, By Application:

Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis on market segmentation. The report provides an in-depth analysis of the Viral Vector and Plasmid DNA Manufacturing market segments. It highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/3817

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Viral Vector and Plasmid DNA Manufacturing market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Read more:
Strategic Analysis to Understand the Competitive Outlook of XYZ Market - 3rd Watch News

Global Gene Therapy Marketencompasses an evaluation of distinct parameters that elevate the growth of the global industry. The major topics of globalGene Therapymarket document can be given as: Overview of industry, development, and manufacturing plants analysis, major manufacturers analysis, development trend analysis, manufacturing cost structure analysis, key figures of major manufacturers, market dynamics, segment market analysis by type and by application, and regional market analysis, market forecast for 2020 to 2025 time-period. The report explains market restraints, key drivers, and industry trends that transform the international market either positively or negatively.

NOTE: Our final report will be revised to address COVID-19 effects on the specific market.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/376052/request-sample

Market Analysis And Insights:

Various companies are covered to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Additionally, competitive analysis and trends, mergers & acquisitions, and expansion strategies are derived. The report contains the overall market overview on globalGene Therapymarket dynamics, historic volume and value, robust market methodology, current & future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure.

The report focuses on top manufacturers in the global market, involved the assessment of sales, price, revenue, and market share for each manufacturer:Spark Therapeutics LLC, Bluebird Bio, UniQure N.V., Juno Therapeutics, GlaxoSmithKline, Chiesi Farmaceutici S.p.A., Bristol Myers Squibb, Celgene Corporation, Human Stem Cell Institute, Voyager Therapeutics, Shire Plc, Sangamo Biosciences, Dimension Therapeutics and others.

By regions, this report splits the globalGene Therapymarket into several key regions, with sales, revenue, price, and gross margin market share of top players in these regions, like:North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Based on the end users/applications and product types, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share, and growth rate for each application and product type. Additionally, the report focuses on the product value trends and so the profit margins of each firm among the globalGene Therapyindustry.

BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.html

TheGene TherapyMarket With Respect To The Geographical Terrain:

The report thoroughly examines the market with reference to geographical topography, which divided intoGene Therapy. Details about the sales acquired by each region as well as their market share are discussed in the report. This research highlights key insights that will affect the growth of every region and revenue generated by listed geographies over the projected timeframe.

The overall report presents a study of the global industry trends, historical data, projections for the coming years, and anticipation of compound annual growth rates (CAGRs) by the end of the forecast period. It discovers new market prospects and targeted marketing methodologies for globalGene Therapy. R&D and the demand for new product launches and applications are further discussed. The report includes a study of the market in terms of generic and premium product revenue.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Here is the original post:
Global Gene Therapy Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 - Galus Australis

SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced final efficacy and safety data from its Phase 2b trial of DalcA, a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of Hemophilia B. The poster was presented at the World Foundation of Hemophilia Virtual Summit, taking place from June 14 -19, 2020.

The poster, entitled: Phase 2b Trial to evaluate the safety and factor IX levels of a daily subcutaneous prophylaxis treatment regimen of dalcinonacog alfa in Hemophilia B presented by Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer, Catalyst Biosciences highlights results from the study.

Data from the trial showed that 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of >12% in all participants, with FIX levels of up to 27% and a half-life of 2.5 to 5.1 days with no bleeds, demonstrating effective prophylaxis and the potential for lower or less frequent dosing. Injection volumes were less than 1 mL. One subject withdrew on day 7 after reporting injection site reactions (ISR) from the first 3 SQ doses. No neutralizing anti-drug antibodies were detected and no serious adverse events were reported. Some subjects reported mild ISR of pain and/or redness, primarily with the initial injections. No thrombotic events occurred and blood coagulation markers of d-dimer, prothrombin fragment 1+2, thrombin-antithrombin and fibrinogen did not show any prothrombotic signals.

The trial data showed excellent efficacy and a clean safety profile, all subjects achieved steady state FIX activity levels exceeding the primary endpoint of 12%. A simple, small volume SQ therapy to provide protective, FIX levels is a potentially transformational improvement in the management of Hemophilia B, said Nassim Usman, Ph.D., president and chief executive officer of Catalyst.

The trial was designed to evaluate daily SQ dosing and the ability to maintain protective steady state FIX levels above 12% in six individuals with severe Hemophilia B. Each subject received a single intravenous dose, followed by daily SQ doses of DalcA for 28 days whereby the pharmacokinetics, pharmacodynamics, safety, tolerability and anti-drug antibody formation were monitored.

A copy of the poster can be accessed on the Events and Presentations section of the Catalyst website.

About Catalyst BiosciencesCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and systemic complement-mediated disorders. Our protease engineering platform includes development programs in hemophilia, a research program on SQ systemic complement inhibitors and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). One of our key competitive advantages is that the product candidates generated by our protease engineering platform have improved functionality and potency. These characteristics allow for improved dosing of our candidates including SQ systemic administration of recombinant coagulation factors and complement inhibitors, low-dose, high activity gene therapy constructs, and less frequently dosed intravitreal therapeutics. Our most advanced asset, SQ MarzAA has successfully completed Phase 2 development in prophylaxis, significantly reducing the annualized bleed rate (ABR) in individuals with Hemophilia A or B with inhibitors. Following regulatory guidance from the FDA and EMA, we recently announced the design of a Phase 3 registration study that is planned for late 2020. Subcutaneous dalcinonacog alfa (DalcA) is being developed for the treatment of Hemophilia B and has demonstrated efficacy and safety in a Phase 2b clinical trial. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry AMD. For more information, please visit http://www.catalystbiosciences.com.

Story continues

Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential for SQ DalcA to transform treatment for patients with Hemophelia B, plans to enroll the begin the Phase 3 trial of MarzAA in late 2020, the potential uses and benefits of MarzAA and DalcA to effectively and therapeutically treat hemophilia subcutaneously, the superiority of CB 2679d-GT over other gene therapy candidates and the Companys collaboration with Biogen for the development and commercialization of pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry age-related macular degeneration. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of the COVID-19 virus and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of DalcA or MarzAA, including the generation of neutralizing antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Companys products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalysts agreement, competition and other risks described in the Risk Factors section of the Companys quarterly report filed with the Securities and Exchange Commission on May 11, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:Ana KaporCatalyst Biosciences, Inc.investors@catbio.com

Read more from the original source:
Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) at the World Federation of...

On Tuesday, June 16, 2020,Wade Chien, M.D., will discuss the exciting field of gene therapy research and its potential promise for treating some forms of hearing and balance disorders. There is no cure for hearing loss, although technologies such as hearing aids and cochlear implants can help some people hear better. Moreover, few options are available for those with chronic balance disorders. Scientists are seeking treatments to replace or repair damaged hair cells in the inner ear that are responsible for a range of hearing and balance disorders. Dr. Chiens lab is using gene therapy techniques in mice to try to stop the symptoms of these disordersand to treat or reverse damage to the inner ear caused by gene mutations.

This lecture is part of a series of talks led by researchers from the National Institute on Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health, called Beyond the Lab, Understanding Communication Disorders. The speaker series is an opportunity for everyone inside and outside of the NIHadministrative staff, support staff, scientists, and the publicto learn about the NIDCDs recent advances in communication disorders, conditions that significantly affect about 20 percent of U.S. adults during their lifetime.

Enhanced microscopic image showing hair-like projections (stereocilia) on the sensory hair cells in the inner ear of a mouse model treated with inner ear gene therapy. The mouse has a genetic form of deafness that causes the stereocilia to be short and defective. Gene therapy elongated the stereocilia and improved hearing.

Source: Kevin Isgrig, NIDCD

Dr. Chien is an NIDCD otolaryngology (diseases of the ear and throat) surgeon-scientist, and principal investigator of the NIDCD Inner Ear Gene Therapy Program. Dr. Chiens lab uses mouse models of hearing and balance disorders to test how sensory hair cells in the inner ear respond to gene therapy. He will discuss exciting recent work from his lab on inner ear gene therapy for deafness and dizziness.

Hearing loss is central to the mission of the NIDCD. Researchers have identified dozens of genetic factors associated with hearing loss.

This live webcast will be captioned and will be available for later viewing. Individuals with disabilities who need sign language interpreting and/or other reasonable accommodations to participate in this eventshould contact Lonnie Lisle (telephone: 240-464-4355) and/or the Federal Relay (800-877-8339) by June 11.

About the Speaker

Wade Chien, M.D., joined the NIDCD as an investigator in the Otolaryngology Surgeon-Scientist Program in 2011. He is also an associate professorin the department of otolaryngology-head and neck surgery at the Johns Hopkins School of Medicine. He received bachelor's degrees in biology and music from Brandeis University and an M.D. from the University of Southern California Keck School of Medicine. He completed otolaryngology residency training in the Harvard Combined Otolaryngology Residency Program at Massachusetts Eye and Ear Infirmary, and a neurotology fellowship at the Johns Hopkins Hospital. He is an alumnus of the Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, during which he worked with Dr. Gerald Fischbach to study the effects of neurotrophins in the neuromuscular junction. He is also a recipient of an NIH T32 training grant in residency, during which he studied middle ear mechanics under the guidance of Dr. Saumil Merchant and Dr. John Rosowski.

See the rest here:
June 16 Beyond the Lab speaker series: The promise of gene ...

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions, announced that it has initiated a research program with the Horae Gene Therapy Center at the UMass Medical School, in Worcester, MA, for gene therapy research in rare genetic diseases, with a focus on neuromuscular conditions. The research program will be under the direction of Guangping Gao, PhD, Co-Director, Li Weibo Institute for Rare Diseases Research, Director, the Horae Gene Therapy Center and Viral Vector Core, Professor of Microbiology and Physiological Systems and Penelope Booth Rockwell Professor in Biomedical Research at UMass Medical School. Dr. Gao is a groundbreaking gene therapy researcher who played a key role in the discovery and characterization of adeno-associated virus (AAV) serotypes now widely used in the field.

CANbridge also announced the addition of Guangping Gao, PhD. and Mark Bamforth, an industry veteran and founder and former CEO of Brammer Bio, to its recently-expanded Strategic Advisory Board.

This collaboration with the Horae Gene Therapy Center at UMass, a pioneer in gene therapy research, affords CANbridge the potential to extend our rare disease pipeline by integrating next-generation technology as we advance as a leader in the treatment of rare diseases, said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceuticals Inc. We are thrilled to be partnering with such a world-class institution.

As a longtime leader in the development of gene therapies for rare disease, with expertise in both capsid and genome engineering, Dr. Gao is the ideal partner for CANbridge as we expand our therapeutic capacity in rare genetic diseases, said Richard J. Gregory, PhD, Acting Chief Scientific Officer, CANbridge Pharmaceuticals Inc.

On behalf of everyone at CANbridge, Im very pleased to welcome Guangping Gao and Mark Bamforth, each widely recognized as true global leaders in the broad areas of gene therapy science and manufacturing, to our Strategic Advisory Board, said Jim Geraghty, CANbridge Pharmaceuticals Advisory Board Chair. Together with Mark Goldberg and Rich Gregory, also recognized biotechnology leaders, they give CANbridge an unparalleled foundation for developing breakthrough therapies for patients in China and around the world.

About the Horae Gene Therapy Center at UMass Medical School

The faculty of the Horae Gene Therapy Center is dedicated to developing therapeutic approaches for rare inherited disease for which there is no cure. We utilize state of the art technologies to either genetically modulate mutated genes that produce disease-causing proteins, or introduce a healthy copy of a gene if the mutation results in a non-functional protein.

The Horae Gene Therapy Center faculty is interdisciplinary, including members from the departments of Pediatrics, Microbiology & Physiological Systems, Biochemistry & Molecular Pharmacology, Neurology, Medicine and Ophthalmology. Physicians and PhDs work together to address the medical needs of rare diseases, such as Alpha 1-Antitrypsin Deficiency, Canavan Disease, Tay-Sachs and Sandhoff diseases, Retinitis Pigmentosa, Cystic fibrosis, Lou Gehrig's disease, TNNT1 nemaline myopathy, Rett syndrome, N-Gly 1 deficiency, Pitt-Hopkins syndrome, Marple Syrup Urine Disease, Sialidosis, GM3 synthase deficiency, Huntington's disease, ALS and others. More common diseases such as cardiac arrhythmia and hypercholesterolemia are also investigated. The hope is to treat a wide spectrum of diseases by various gene therapeutic approaches. Additionally, the University of Massachusetts Medical School conducts clinical trials on site and some of these trials are conducted by the investigators at the Gene Therapy center.

About the University of Massachusetts Medical School

The mission of the University of Massachusetts Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery.

For more information, visit http://www.umassmed.edu.

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. is a biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address unmet medical needs.

CANbridge has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, where it is a recognized leader in orphan diseases, CANbridge has an exclusive licensing agreement to commercialize Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. The CANbridge oncology portfolio includes exclusive rights to develop and commercialize Puma Biotechnologys NERLYNX (neratinib), which was recently approved in greater China, as well as rights to other novel candidates.

For more on CANbridge Pharmaceuticals Inc., please go to http://www.canbridgepharma.com.

See the original post here:
CANbridge Pharmaceuticals Enters Into Rare Disease Gene ...

The same day Oxford Biomedica signed a 5-year deal to make AstraZenecas Covid-19 vaccine, the UK gene therapy company announced they received word Sanofi was sending a couple of decade-old experimental drugs back to them.

In 2009, Sanofi and Biomedica slashed a co-development deal on TroVax, a cancer vaccine that had been one of the centerpieces of the then 14-year-old company. But the pair immediately replaced it with a deal, 8 years before the approval of Spark Therapeutics Luxturna, to develop gene therapies for two eye-related disorders.

Now, with little to show for it but a pair of very early studies, Sanofi is kicking the therapies back to Biomedica. The French drugmaker had already announced last year, amid an internal shakeup, that they were not interested in developing the drugs further, but what would happen to the therapies hung in the air.

In some ways, it still does. Biomedica wouldnt commit to progressing or retiring them. It wasnt even clear when Biomedica would regain the rights.

The timing of return of these programs and operational details are yet to be determined, the biotech said in a statement. However, when the rights to the two programs are returned, the group will undertake its own internal evaluation to determine the potential future for these programs and decide whether to commit further resources to them.

Biomedicas $100 million partnership with Sanofis rare blood disorder subsidiary Bioverativremains intact.

The two gene therapies are SAR422459, for treating a progressive macular disease called Stargardt disease, and SAR421869, for treating Ushers Syndrome, a disorder that can cause both vision and hearing loss. The Stargardt therapy began a Phase I/II study in France in 2011, but the study was ended prematurely last August after Sanofi reprioritized its pipeline. Although the study was designed to measure biological markers of efficacy, Sanofi included no such data when it posted results on clinicaltrials.gov earlier this year.

The therapy for Ushers Syndrome entered its Phase I/II study in 2012. That study was suspended in 2017 while Sanofi reviewed its pipeline and then also terminated last year.

If Biomedica considers the therapies to still have potential, its likely they will try to out-license them again. The company is built around partnerships, licensing out a few in-house candidates and helping manufacture Novartiss CAR-T therapy Kymriah and, as of yesterday, AstraZenecas Covid-19 vaccine. They areexplicitly not a commercial-stage biotech.All of the preclinical candidates on its website are listed as to be spun out, or out-licensed, and they run no clinical trials.

So the best question may be not whether Biomedica sees potential, but if anyone else does.

Social: Shutterstock

Follow this link:
Sanofi sends a pair of gene therapies back to Oxford Biomedica. Are they salvageable? - Endpoints News

Global Gene Therapy for Inherited Genetic Disorders Market: Trends Estimates High Demand by 2027

The Gene Therapy for Inherited Genetic Disorders Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Gene Therapy for Inherited Genetic Disorders Industry Report is an in-depth study analyzing the current state of the Gene Therapy for Inherited Genetic Disorders Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Gene Therapy for Inherited Genetic Disorders Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Gene Therapy for Inherited Genetic Disorders market. All findings and data on the global Gene Therapy for Inherited Genetic Disorders market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Gene Therapy for Inherited Genetic Disorders market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Gene Therapy for Inherited Genetic Disorders industry.

Some of The Companies Competing in The Gene Therapy for Inherited Genetic Disorders Market are: BioMarin Pharmaceutical Inc., bluebird bio Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics Inc., and

Get a Sample Copy of the [emailprotected] https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-gene-therapy-for-inherited-genetic-disorders-market-size-status-and-forecast-2020-2026?utm_source=3wnews&utm_medium=24

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Gene Therapy for Inherited Genetic Disorders Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and improvement plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Gene Therapy for Inherited Genetic Disorders Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Gene Therapy for Inherited Genetic Disorders market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Gene Therapy for Inherited Genetic Disorders market report answer pertaining to the regional reach of the industry?

The report claims to split the regional scope of the Gene Therapy for Inherited Genetic Disorders market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present how does the sales scenario look for the future?

Considering the present scenario, how much revenue will each region attain by the end of the forecast period?

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Gene Therapy for Inherited Genetic Disorders market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Gene Therapy for Inherited Genetic Disorders Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Gene Therapy for Inherited Genetic Disorders Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Gene Therapy for Inherited Genetic Disorders Market Effect Factors Analysis

Chapter 12: GlobalGene Therapy for Inherited Genetic Disorders Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-gene-therapy-for-inherited-genetic-disorders-market-size-status-and-forecast-2020-2026?utm_source=3wnews&utm_medium=24

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read the rest here:
Research on Gene Therapy for Inherited Genetic Disorders Market (impact of COVID-19) with Top Players: BioMarin Pharmaceutical Inc., bluebird bio...

MINNEAPOLIS, June 10, 2020 /PRNewswire/ -- Be The Matchtoday announced the appointment of Amy Ronneberg as chief executive officer (CEO)the first female CEO for the organization. Ronneberg joined Be The Match in 2013 as chief financial officer (CFO) and chief of staff, and has served as acting CEO since February.

Be The Match is a non-profit organization that delivers cures to patients in need of life-saving blood stem cell therapy. The organization operates the national Be The Match Registry,the world's largest and most diverse listing of potential stem cell donors. As trusted leaders in advancing stem cell therapy, Be The Match also provides ground-breaking research, innovative technologies, patient support, and education so even more lives can be saved.

Around the same time Ronneberg joined Be The Match as CFO, she was diagnosed with breast cancer. Now cancer-free, she brings unique passion and perspective to her work.

"As a cancer survivor, I have personally felt what many other cancer patients and their loved ones encounter every day. My experience, the patients we serve, and our outstanding, dedicated employees are my motivation," Ronneberg said. "I am deeply honored to be selected to lead this organization and look forward to further advancing our commitment to providing equal outcomes for all. The recent pandemic has put a spotlight on healthcare inequalities, and we are uniquely positioned to address one glaring disparity that is affecting ethnically diverse patientsthat is the ability to find a matching donor. I look forward to leading our team in diversifying the registry and delivering more life-saving treatments to patients of all backgrounds."

After the Affordable Care Act was implemented, Ronneberg led a Be The Match budget restructure that netted a sustainable $50 million cost reduction and made marrow transplants more affordable. Those efforts and more earned her one of the Minneapolis/St. Paul Business Journal's 2016 CFO of the Year awards. Ronneberg also played a pivotal role in establishing Be The Match's operations in Mexico.

This spring, the Be The Match Board of Directors worked with an outside firm to identify the qualities needed in its next CEO and unanimously agreed that Ronneberg possesses all of them.

"Amy has the perfect blend of business experience, passion and health care expertise to lead Be The Match," said Chair of the Board David L. Porter, M.D. "She likes to say, 'patients first, employees always.' I applaud her commitment to carrying out our mission and putting people first."

Ronneberg is also responsible for Be The Match BioTherapies, which partners with global cell and gene therapy industry leaders to deliver high-quality, consistent and compliant therapies to patients in need. Under her guidance, Be The Match BioTherapies has invested in several therapeutics companies and launched an integrated supply chain platform called MatchSource.

Prior to joining Be The Match, Ronneberg spent 12 years at Capella Education Company where she served as chief accounting officer, vice president of finance and led enterprise-wide operations and customer service. She also worked for Ernst & Young as an audit manager.

Ronneberg has served on several boards and is currently on the board of Magenta Therapeutics (MGTA) and the Finance Committee for Allina Healthcare and the World Marrow Donor Association.

Ronneberg earned a Master of Business Administration from Capella University, Minneapolis, Minn. and a Bachelor of Business Administration in Accounting from University of Wisconsin-Eau Claire.

"Going through treatment with my husband and young children at my side made me a much stronger person, leader and decision maker," Ronneberg said. "Cancer is an unfortunate reality that millions of people have to face, but with support, hope and the right medical tools, it can be overcome."

About Be The MatchFor people with life-threatening blood cancerslike leukemia and lymphomaor other diseases, a cure exists. Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. People can contribute to the cure as a member of the Be The Match Registry, financial contributor or volunteer. Be The Match provides patients and their families one-on-one support, education, and guidancebefore, during and after transplant.

Be The Match is operated by the National Marrow Donor Program (NMDP), a nonprofit organization that matches patients with donors, educates health care professionals and conducts research through its research program, CIBMTR (Center for International Blood and Marrow Transplant Research), so more lives can be saved. To learn more about the cure, visit BeTheMatch.orgor call 1 (800) MARROW-2.

Read this article:
Be The Match Appoints Amy Ronneberg as Chief Executive Officer - Southernminn.com

Related ResearchSarepta Therapeutics Inc., a leader in precision genetic medicine for rare diseases, plans to invest over $30 million to expand its Gene Therapy Center of Excellence in Columbus, Ohio. The project is expected to create 100 new jobs.

Pending state approvals, Sarepta plans to open its new center in an 85,000-square-foot facility at 3435 Stelzer Road in Columbus. All employees currently operating out of the Companys Dublin, Ohio, office will transition to the new facility over time. Armed with the most advanced science in genetic medicine, the new center will allow Sarepta to lead the way in making Columbus an epicenter of gene therapy research and development. In addition to the new building, the companys investment will be used toward R&D equipment.

Sarepta is emerging as the world leader in gene therapy to treat and transform lives otherwise diminished and stolen by rare genetic disease. We are confident that gene therapy will revolutionize genetic medicine, and we chose Ohio for our Gene Therapy Center of Excellence because we believe Columbus will become a hub for genetic medicine innovation, said Sarepta President & CEO Doug Ingram. Our new center will strengthen the position of Columbus as a gene therapy leader, building on the advances of our long-standing partner, Nationwide Childrens Hospital.

We are proud to be the home of Sareptas new Gene Therapy Center of Excellence and to support their continued innovation within a critical field in medicine, said Columbus Mayor Andrew J. Ginther. The companys investment in Columbus is a testament to why our city and region are positioned to become the most important place in the world for gene therapy development.

From medical breakthroughs to cutting-edge technology, the Columbus Region is home to one of the top healthcare industries in the country. With several renowned healthcare systems and companies, including OhioHealth, Nationwide Childrens Hospital and Cardinal Health, the Columbus Region employs more than 45,000 in the industry. The Regions large pool of IT talent, combined with its well-established healthcare sector, makes it a hotbed for innovation.

Sarepta is one of the nations fastest growing biotechnology companies focused on the development of precision genetic medicines, said JobsOhio President and CEO J.P. Nauseef. With Ohio talent, Sarepta will advance its R&D of neuromuscular and central nervous system diseases at its new gene therapy R&D Center in the Columbus Region.

Founded in 1980, Sarepta develops genetic medicines to treat rare diseases, and currently has two approved products for Duchenne muscular dystrophy (DMD) and a pipeline of more than 40 treatments in development. The companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.

Headquartered in Cambridge, Massachusetts, Sarepta has locations across four continents, and its current Central Ohio research facility in Dublin employs approximately 40 full-time workers.

Read more:
Sarepta Therapeutics Expands Gene Therapy Center of Excellence in Columbus, Ohio - Area Development Online

The report covers the forecast and analysis of the Cell and Gene Therapy Consumables market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the Cell and Gene Therapy Consumables market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Cell and Gene Therapy Consumables market on a global level.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10172657

In order to give the users of this report a comprehensive view of the Cell and Gene Therapy Consumables market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service & product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the Cell and Gene Therapy Consumables market by segmenting the market based on product type, application/therapeutics, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

A rise in the awareness about the gene & cell therapies will propel the market growth during the period from 2019 to 2027. Nevertheless, conducting randomized control tests will inhibit the expansion of the market during the forecast timeline. However, the growing trend for treating neurodegenerative ailments through the use of gene treatment will proliferate the market growth over the forecast period.

The expansion of the market during the forecast timespan is owing to the high frequency of chronic ailments including cancer and heart disorders. Apart from this, inflation in the occurrence of these disorders produces lucrative demand for enhanced therapies and this will culminate in the market demand over the forecast timespan.

Request For Full Report:https://www.kennethresearch.com/sample-request-10172657

Based on the product type, the market is sectored into Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media. Application/ Therapeutics- wise, the market for cell and gene therapy consumables are classified into Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology.

Some of the key players in the market include Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook, Dendreon Pharmaceuticals, LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc., Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, Helixmith Co., Ltd., and Vitrolife.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

See the rest here:
Cell and Gene Therapy Consumables Market Top Key Players, Drivers and Trends to 2027 - Cole of Duty

The Global Gene Therapy Market was estimated to be valued at USD XX million in 2019 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026.

The market is primarily driven by increase in funding for R&D activities pertaining to gene therapy and increase in awareness regarding gene therapy.

In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer is likely to fuel the market growth.

Get Sample Copy of this Report @ http://www.orianresearch.com/requestle/1043835

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Top Key Companies Analyzed inGlobal Gene Therapy Market are Novartis, Kite Pharma Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica and NewLink Genetics Corp

Key Benefit of This Report:

Global Gene Therapy Industry 2019 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share a question if any before the purchase on this report @ http://www.orianresearch.com/1043835

Target Audience:

Research Methodology:

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration.

Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:

Get Direct Copy of this Report @ http://www.orianresearch.com/checkout/1043835

Major Points Covered in Table of Contents:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Global Gene Therapy Market Overview

5 Global Gene Therapy Market, by Vector

6 Global Gene Therapy Market, by Application

7 Global Gene Therapy Market by Region

8 Competitive Landscape

9 Company Profiles

10 Key Insights

Customization Service of the Report:Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:Ruwin MendezVice President Global Sales & Partner RelationsOrian Research ConsultantsUS: +1 (832) 380-8827 | UK: +44 0161-818-8027Email:[emailprotected]Website: http://www.orianresearch.com/

Read more from the original source:
COVID-19 Impact on Global Gene Therapy Industry 2020: Market Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players and Forecast...

- Six-month data from low-dose cohort expected in Q4 2020

- IND amended to include Type I (infantile onset) patients and to evaluate a higher dose - Expect to initiate high-dose cohort in 2H 2020

NEW YORK and BASEL, Switzerland, June 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has completed enrollment in the low-dose cohort of the Phase 1/2 (Stage 1”) study for Type II (late infantile and juvenile onset) GM1 patients evaluating safety, tolerability, and exploratory measures of efficacy at a dose of 1.5x1013 vg/kg delivered intravenously. Currently, the study is on track to report 6-month data (n=5) from the low-dose cohort of the AXO-AAV-GM1 clinical trial by Q4 2020. Additionally, the investigational new drug (IND) filing has been amended to expand the program to include Type I (infantile) patients and to evaluate a 3-fold higher dose (4.5x1013 vg/kg). The Company expects to initiate dosing in the high-dose cohort, which will include both Type I and Type II patients, in the second half of 2020.

The successful enrollment of the low-dose cohort of the ongoing Phase 1/2 study amidst the COVID-19 pandemic speaks to the dedication of all involved and the significant unmet need that exists for these children,” said Dr. Gavin Corcoran, chief R&D officer. With an expanded study protocol that now includes infantile-onset patients, AXO-AAV-GM1 is the only gene therapy in development to include both Type I and Type II GM1 patients, populations of children who suffer from a deficiency in the same enzyme, -galactosidase. We are grateful for the collaboration and perseverance of the National Institutes of Health (NIH), patients, and their families to advance efforts towards finding a treatment for this devastating pediatric disease.”

This study is being conducted at the NIH under the direction of Dr. Cynthia Tifft, Deputy Clinical Director at the National Human Genome Research Institute (NHGRI) in collaboration with Axovant Gene Therapies. In late 2019, the Company presented an update from the first GM1 Type II child dosed with AXO-AAV-GM1 under an expanded access protocol who was observed to have clinically significant improvements from baseline gene transfer to six-month follow-up based on neurological exam, the Vineland-3 scale, Clinical Global Impression assessments, and nutritional status. In addition, AXO-AAV-GM1 was observed to be generally well-tolerated with no reports of serious adverse events related to the investigational gene therapy or intravenous administration of the vector.

GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disorder caused by mutations in the GLB1 gene leading to impaired production of the -galactosidase enzyme. There are currently no approved treatments for GM1 gangliosidosis.

AXO-AAV-GM1 was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) in November 2019.

About AXO-AAV-GM1

AXO-AAV-GM1 is an investigational gene therapy that delivers a functional copy of the GLB1 gene via an adeno-associated viral (AAV) vector, with the goal of restoring -galactosidase enzyme activity for the treatment of GM1 gangliosidosis. The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease as well. Preclinical studies in murine and a naturally-occurring feline model of GM1 gangliosidosis have supported AXO-AAV-GM1’s ability to improve -galactosidase enzyme activity, reduce GM1 ganglioside accumulation, improve neuromuscular function, and extend survival.

About Axovant Gene Therapies

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit http://www.axovant.com.

In 2018, Axovant licensed exclusive worldwide rights from the University of Massachusetts Medical School (UMMS) for the development and commercialization of gene therapy programs for GM1 gangliosidosis and GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. A three-way Cooperative Research and Development Agreement (CRADA) among Axovant, the NHGRI, and the University of Massachusetts was established in 2019 to support the conduct of the clinical program.

About the University of Massachusetts Medical School

The mission of the University of Massachusetts Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery.

Research into potential therapies for lysosomal storage diseases such as Tay-Sachs, Sandhoff disease and GM1 gangliosidosis at UMass Medical School and Auburn University has led to significant advances in the field. Miguel Sena-Esteves, PhD, associate professor of neurology at UMass Medical School; Heather Gray-Edwards, PhD, DVM, formerly of Auburn and currently assistant professor of radiology at UMass Medical School; and Douglas Martin, PhD, professor of anatomy, physiology and pharmacology in the College of Veterinary Medicine and the Scott-Ritchey Research Center at Auburn University, have worked collaboratively for more than a decade on animal models and therapeutic approaches for these and similar disorders. For more information, visit http://www.umassmed.edu.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "anticipate," "will," "would," "should," "expect," "believe," "estimate," and other similar expressions are intended to identify forward-looking statements. For example, all statements Axovant makes regarding the initiation, timing, progress, and reporting of clinical data for its clinical programs, are forward-looking. All forward-looking statements are based on estimates and assumptions by Axovant’s management that, although Axovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Axovant expected. Such risks and uncertainties include, among others, the initiation and conduct of the AXO-AAV-GM1 program and the availability of data for disclosures; Axovant’s scientific approach and general development, manufacturing and regulatory progress; Axovant’s ability to perform under its existing clinical and business collaborations; and risks of unforeseen operational delays and other uncertainties caused by the COVID-19 pandemic. These statements are also subject to a number of material risks and uncertainties that are described in Axovant’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 10, 2020, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Axovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Media and Investor Contact: Parag Meswani Axovant Gene Therapies (212) 547-2523 investors@axovant.com media@axovant.com

See the original post here:
Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with...

DUBLIN--(BUSINESS WIRE)--The "Bioreactors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Cell; Molecule; Technology; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

The bioreactors market was valued at US$ 2,958.50 million in 2019 and is projected to reach US$ 5,169.01 million by 2027; it is expected to grow at a CAGR of 7.3% from 2020 to 2027. The increasing adoption of single-use bioreactors, and rapid growth of the pharmaceuticals and biotechnology industries are among the prime factors driving the bioreactors market. However, stringent regulatory frameworks hinder the growth of the market.

The use of single-use bioreactors has increased in the modern biopharmaceutical processes in the last few years. This can be attributed to their unique ability to allow enhanced process flexibility, reduce investment requirements, and limit operational costs. Also, many companies have developed single-use bioreactors for the production of a wide range of therapeutics. For instance, Distek Inc., has developed a benchtop single-use bioreactor system for recombinant protein production. Single-use bioreactors reduce the risks of contamination and decrease production turnaround times. Moreover, the reduction in validation time has been one of the prime benefits of single-use bioreactors. The rising adoption of single-use bioreactors for upstream bioprocessing is driving the growth of the market.

The global bioreactors market is segmented on the basis of cell, molecule, technology, and end user. The bioreactors market, by molecule, is segmented into monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy, and others. The monoclonal antibodies segment held the largest share of the market in 2019. However, the stem cell segment is projected to register the highest CAGR in the market during the forecast period. Based on cell, the bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, and others. Based on technology, the market is segmented into wave-induced motion sub, stirred sub, single-use bubble column, and others. Based on end user, the market is segmented into research and development organizations, biopharma manufacturers, contract manufacturing organizations (CMOs).

Key report benefits:

Key Topics Covered:

1. Introduction

2. Bioreactors Market - Key Takeaways

3. Research Methodology

4. Global Bioreactors Market- Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinion

5. Global Bioreactors Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Adoption of Single-Use Bioreactors

5.1.2 Rapid Growth of Pharmaceutical and Biotechnology Industry

5.2 Market Restraints

5.2.1 Stringent Regulatory Framework

5.3 Market Opportunities

5.3.1 Rising Demand of Personalized Medicine

5.4 Future Trends

5.4.1 Technological Advancements in Bioreactors

5.5 Impact analysis

6. Bioreactors Market- Global Analysis

7. Bioreactors Market- By Cell

7.1 Overview

7.2 Bioreactors Market Share, by Cell, 2019 and 2027 (%)

7.3 Mammalian Cells

7.4 Bacterial Cells

7.5 Yeast Cells

7.6 Others

8. Bioreactors Market- By Molecule

8.1 Overview

8.2 Bioreactors Market Share, by Molecule, 2019 and 2027 (%)

8.3 Monoclonal Antibodies

8.4 Vaccines

8.5 Recombinant Proteins

8.6 Stem Cells

8.7 Gene Therapy

8.8 Others

9. Global Bioreactors Market Analysis- By Technology

9.1 Overview

9.2 Global Bioreactors Market, By Technology 2019 & 2027 (%)

9.3 Wave-Induced Motion SUB

9.4 Stirred SUB

9.5 Single-Use Bubble Column

9.6 Other Technologies

10. Global Bioreactors Market Analysis- By End User

10.1 Overview

10.2 Global Bioreactors Market, By End User 2019 & 2027 (%)

10.3 Research And Development Organizations

10.4 Biopharma Manufacturers

10.5 Contract Manufacturing Organisations (CMOs)

11. Bioreactors Market - Geographical Analysis

12. Bioreactors Market - Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

14. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/235ppa

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Read this article:
Global Bioreactors Market Forecast to 2027 - COVID-19 Impact and Analysis by Cell, Molecule, Technology, End User and Geography -...